Potential of Anti-inflammatory Molecules in the Chemoprevention of
Breast Cancer

Vaishnavi      Gadi; Saritha   Rakesh   Shetty
Abstract

Breast cancer is a global issue, affecting greater than 1 million women per annum. Over the past two decades, there have been numerous clinical trials involving the use of various pharmacological substances as chemopreventive agents for breast cancer. Various pre-clinical as well as clinical studies have established numerous anti-inflammatory molecules, including nonsteroidal anti-inflammatory drugs (NSAIDs) and dietary phytochemicals as promising agents for chemoprevention of several cancers, including breast cancer. The overexpression of COX-2 has been detected in approximately 40% of human breast cancer cases and pre-invasive ductal carcinoma in-situ lesions, associated with aggressive elements of breast cancer such as large size of the tumour, ER/PR negative and HER-2 overexpression, among others. Anti-inflammatory molecules inhibit COX, thereby inhibiting the formation of prostaglandins and inhibiting nuclear factor-κBmediated signals (NF-kB). Another probable explanation entails inflammation-induced degranulation, with the production of angiogenesis-regulating factors, such as vascular endothelial growth factor, which can be possibly regulated by anti-inflammatory molecules. Apart from NSAIDS, many dietary phytochemicals have the ability to decrease, delay, or stop the progression and/or incidence of breast cancer by their antioxidant action, regulating inflammatory and proliferative cell signalling pathways as well as inducing apoptosis. The rapid progress in chemoprevention research has also established innovative strategies that can be implemented to prevent breast cancer. This article gives a comprehensive overview of the recent advancements in using antiinflammatory molecules in the chemoprevention of breast cancer along with their mechanism of action, supported by latest preclinical and clinical data. The merits of anti-inflammatory chemopreventive agents in the prevention of cardiotoxicity have been described. We have also highlighted the ongoing research and advancements in improving the efficacy of using antiinflammatory molecules as chemopreventive agents.
Keywords: NSAIDs, COX-2 inhibitor, dietary phytochemical, anti-oxidant, apoptosis, angiogenesis, prostaglandin, chemopreventive.
Graphical Abstract

[1]
Macdonald S, Oncology R, General M. Breast cancer. J R Soc Med  2016; 70(8): 515-7. Available from: https://www2.trikobe.org/nccn/guideline/breast/english/breast.pdf

[2]
Harbeck N, Gnant M. Breast cancer. Lancet  2017; 389(10074): 1134-50.
 [http://dx.doi.org/10.1016/S0140-6736(16)31891-8] [PMID:  27865536]

[3]
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin  2019; 69(6): 438-51.
 [http://dx.doi.org/10.3322/caac.21583] [PMID:  31577379]

[4]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin  2021; 71(3): 209-49.
 [http://dx.doi.org/10.3322/caac.21660] [PMID:  33538338]

[5]
Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: An overview. Updates Surg  2017; 69(3): 313-7.
 [http://dx.doi.org/10.1007/s13304-017-0424-1] [PMID:  28260181]

[6]
Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast  2015; 24 (Suppl. 2): S149-53.
 [http://dx.doi.org/10.1016/j.breast.2015.07.035] [PMID:  26299406]

[7]
Muss HB. Adjuvant chemotherapy in older women with breast cancer: Who and what? J Clin Oncol  2014; 32(19): 1996-2000.
 [http://dx.doi.org/10.1200/JCO.2013.54.8586] [PMID:  24868030]

[8]
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res  2017; 50(1): 33.
 [http://dx.doi.org/10.1186/s40659-017-0140-9] [PMID:  28969709]

[9]
Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis  2000; 21(3): 525-30.
 [http://dx.doi.org/10.1093/carcin/21.3.525] [PMID:  10688873]

[10]
Sugimura T. An overview of cancer prevention. Eur J Cancer Prev  1996; 5 (Suppl. 2): 1-8.
 [http://dx.doi.org/10.1097/00008469-199612002-00001] [PMID:  9061288]

[11]
Cuzick J. Chemoprevention of breast cancer.  (2nd ed.). Manag Breast Dis 2016; pp. 593-600.

[12]
Rao C, Reddy B. NSAIDs and chemoprevention. Curr Cancer Drug Targets  2004; 4(1): 29-42.
 [http://dx.doi.org/10.2174/1568009043481632] [PMID:  14965265]

[13]
Bhat KPL, Pezzuto JM. Natural modulators of estrogen biosynthesis and function as chemopreventive agents. Arch Pharm Res  2001; 24(6): 473-84.
 [http://dx.doi.org/10.1007/BF02975150] [PMID:  11794520]

[14]
Chung SH, Woldenberg N, Roth AR, et al. Brca and beyond: Comprehensive image-rich review of hereditary breast and gynecologic cancer syndromes. Radiographics  2020; 40(2): 306-25.
 [http://dx.doi.org/10.1148/rg.2020190084] [PMID:  32031911]

[15]
Iwase T, Wang X, Shrimanker TV, Kolonin MG, Ueno NT. Body composition and breast cancer risk and treatment: Mechanisms and impact. Breast Cancer Res Treat  2021; 186(2): 273-83.
 [http://dx.doi.org/10.1007/s10549-020-06092-5] [PMID:  33475878]

[16]
Zappavigna S, Cossu AM, Grimaldi A, et al. Anti-inflammatory drugs as anticancer agents. Int J Mol Sci  2020; 21(7): 2605.
 [http://dx.doi.org/10.3390/ijms21072605] [PMID:  32283655]

[17]
Kashyap D, Garg VK, Tuli HS, et al. Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules  2019; 9(5): 174.
 [http://dx.doi.org/10.3390/biom9050174] [PMID:  31064104]

[18]
Senousy HH, Abd Ellatif S, Ali S. Assessment of the antioxidant and anticancer potential of different isolated strains of cyanobacteria and microalgae from soil and agriculture drain water. Environ Sci Pollut Res Int  2020; 27(15): 18463-74.
 [http://dx.doi.org/10.1007/s11356-020-08332-z] [PMID:  32193737]

[19]
Youlden DR, Cramb SM, Dunn NAM, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol  2012; 36(3): 237-48.
 [http://dx.doi.org/10.1016/j.canep.2012.02.007] [PMID:  22459198]

[20]
Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol  2016; 59(4): 651-72.
 [http://dx.doi.org/10.1097/GRF.0000000000000239] [PMID:  27681694]

[21]
Abdelwahab Yousef AJ. Male breast cancer: Epidemiology and risk factors. Semin Oncol  2017; 44(4): 267-72.
 [http://dx.doi.org/10.1053/j.seminoncol.2017.11.002] [PMID:  29526255]

[22]
van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr)  2011; 34(2): 71-88.
 [http://dx.doi.org/10.1007/s13402-011-0010-3] [PMID:  21336636]

[23]
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2 -Associated Hereditary Breast and Ovarian Cancer Summary Genetic counseling Suggestive Findings.  Seattle: GeneReviews, Univ Washington 1998; pp. 1-37.

[24]
Kabel AM, Baali FH. Breast cancer: Insights into risk factors, pathogenesis, diagnosis and management. J Cancer Res Treat  2015; 3: 28-33. Available from: http://pubs.sciepub.com/jcrt/3/2/3/index.html%0Apubs.sciepub.com/jcrt/3/2/3/abstract.html

[25]
Knowledge BC, Practices S, Morse EP, Maegga B, Joseph G, Miesfeldt S. Breast Cancer: Basic and clinical research  2014; 73-9.

[26]
Watkins EJ. Overview of breast cancer. JAAPA  2019; 32(10): 13-7.
 [http://dx.doi.org/10.1097/01.JAA.0000580524.95733.3d] [PMID:  31513033]

[27]
Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines. ISRN Inflamm  2013; 2013: 1-12.
 [http://dx.doi.org/10.1155/2013/139239] [PMID:  24455420]

[28]
Crespi E, Bottai G, Santarpia L. Role of inflammation in obesity-related breast cancer. Curr Opin Pharmacol  2016; 31: 114-22.
 [http://dx.doi.org/10.1016/j.coph.2016.11.004] [PMID:  27889687]

[29]
Deshmukh SK, Srivastava SK, Poosarla T, et al. Inflammation, immunosuppressive microenvironment and breast cancer: Opportunities for cancer prevention and therapy. Ann Transl Med  2019; 7(20): 593-3.
 [http://dx.doi.org/10.21037/atm.2019.09.68] [PMID:  31807574]

[30]
Mohamed HT, El-Shinawi M, Nouh MA, et al. Inflammatory breast cancer: High incidence of detection of mixed human cytomegalovirus genotypes associated with disease pathogenesis. Front Oncol  2014; 4(SEP): 246.
 [http://dx.doi.org/10.3389/fonc.2014.00246] [PMID:  25309872]

[31]
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin  2014; 64(1): 52-62.
 [http://dx.doi.org/10.3322/caac.21203] [PMID:  24114568]

[32]
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci  2017; 13(11): 1387-97.
 [http://dx.doi.org/10.7150/ijbs.21635] [PMID:  29209143]

[33]
Cazzaniga M, Bonanni B. Breast cancer chemoprevention: Old and new approaches. J Biomed Biotechnol  2012; 2012

[34]
Daly MB. Breast cancer chemoprevention. Breast Cancer Risk Reduct Early Detect  2010; 43-59.

[35]
Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res  2011; 31(12): 4359-67.
 [PMID:  22199301]

[36]
Li X, Gao L, Cui Q, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene  2012; 31(48): 4979-86.
 [http://dx.doi.org/10.1038/onc.2011.655] [PMID:  22286762]

[37]
Bertrand KA, Bethea TN, Gerlovin H, et al. Aspirin use and risk of breast cancer in African American women. Breast Cancer Res  2020; 22(1): 96.
 [http://dx.doi.org/10.1186/s13058-020-01335-1] [PMID:  32887656]

[38]
Hu C, Li M, Guo T, et al. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT. Phytomedicine  2019; 58: 152740.
 [http://dx.doi.org/10.1016/j.phymed.2018.11.001] [PMID:  31005718]

[39]
Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev  2019; 39(1): 114-45.
 [http://dx.doi.org/10.1002/med.21514] [PMID:  29855050]

[40]
Yiannakopoulou EC. Aspirin and NSAIDs for breast cancer chemoprevention. Eur J Cancer Prev  2015; 24(5): 416-21.
 [http://dx.doi.org/10.1097/CEJ.0000000000000098] [PMID:  25380191]

[41]
Horn SL, Fentiman IS. The role of non-steroidal anti-inflammatory drugs in the chemoprevention of breast cancer. Pharmaceuticals (Basel)  2010; 3(5): 1550-60.
 [http://dx.doi.org/10.3390/ph3051550] [PMID:  27713317]

[42]
Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: Current evidence and future perspectives. Breast Care (Basel)  2016; 11(5): 339-44.
 [http://dx.doi.org/10.1159/000452315] [PMID:  27920627]

[43]
Davies GLS. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol  2003; 86(3-5): 495-9.
 [http://dx.doi.org/10.1016/j.jsbmb.2003.07.004] [PMID:  14623549]

[44]
Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. 2003; 524: 137-44.
 [http://dx.doi.org/10.1016/S0027-5107(02)00329-9]

[45]
Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res  1996; 56(19): 4424-9.
 [PMID:  8813136]

[46]
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res  2003; 110(5-6): 255-8.
 [http://dx.doi.org/10.1016/S0049-3848(03)00379-7] [PMID:  14592543]

[47]
Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia  2015; 20(3-4): 109-19.
 [http://dx.doi.org/10.1007/s10911-015-9333-4] [PMID:  26193871]

[48]
Subbaramaiah K, Hudis CA, Dannenberg AJ. The prostaglandin transporter regulates adipogenesis and aromatase transcription. Cancer Prev Res (Phila)  2011; 4(2): 194-206.
 [http://dx.doi.org/10.1158/1940-6207.CAPR-10-0367] [PMID:  21212407]

[49]
Brodie AMH, Lu Q, Long BJ, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol  2001; 79(1-5): 41-7.
 [http://dx.doi.org/10.1016/S0960-0760(01)00131-5] [PMID:  11850206]

[50]
Brueggemeier RW, Díaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol  2005; 95(1-5): 129-36.
 [http://dx.doi.org/10.1016/j.jsbmb.2005.04.013] [PMID:  15964185]

[51]
Kehm RD, Hopper JL, John EM, et al. Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study. Breast Cancer Res  2019; 21(1): 52.
 [http://dx.doi.org/10.1186/s13058-019-1135-y] [PMID:  30999962]

[52]
Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast  2011; 20(1): 66-70.
 [http://dx.doi.org/10.1016/j.breast.2010.07.004] [PMID:  20724158]

[53]
Benoit V, Relic B, Leval X, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene  2004; 23(8): 1631-5.
 [http://dx.doi.org/10.1038/sj.onc.1207295] [PMID:  14985703]

[54]
Clarke CA, Canchola AJ, Moy LM, et al. Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: The California Teachers Study. Breast Cancer Res  2017; 19(1): 52.
 [http://dx.doi.org/10.1186/s13058-017-0840-7] [PMID:  28460643]

[55]
Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast  2006; 15(3): 390-8.
 [http://dx.doi.org/10.1016/j.breast.2005.06.011] [PMID:  16169726]

[56]
Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: Common targets and common goals. Expert Opin Investig Drugs  2004; 13(10): 1327-38.
 [http://dx.doi.org/10.1517/13543784.13.10.1327] [PMID:  15461561]

[57]
Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res  2000; 60(8): 2101-3.
 [PMID:  10786667]

[58]
Li J, Hao Q, Cao W, Vadgama JV, Wu Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res  2018; 10: 4653-67.
 [http://dx.doi.org/10.2147/CMAR.S178567] [PMID:  30464589]

[59]
Nakatsugi S, Ohta T, Kawamori T, et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res  2000; 91(9): 886-92.
 [http://dx.doi.org/10.1111/j.1349-7006.2000.tb01030.x] [PMID:  11011115]

[60]
Kubatka P, Ahlers I, Ahlersová E, et al. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett  2003; 202(2): 131-6.
 [http://dx.doi.org/10.1016/j.canlet.2003.08.006] [PMID:  14643442]

[61]
Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res  2007; 13(18): 5488-96.
 [http://dx.doi.org/10.1158/1078-0432.CCR-07-0404] [PMID:  17875779]

[62]
Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Res  1999; 19(4B): 3031-6.
 [PMID:  10652588]

[63]
Hung CH, Lin YC, Chang YH, et al. The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases. Eur J Cancer Prev  2019; 28(5): 428-34.
 [http://dx.doi.org/10.1097/CEJ.0000000000000476] [PMID:  30339576]

[64]
Kim S, Shore DL, Wilson LE, et al. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: Results from a prospective study of women with a sister with breast cancer. BMC Cancer  2015; 15(1): 960.
 [http://dx.doi.org/10.1186/s12885-015-1979-1] [PMID:  26673874]

[65]
Khan MS, Khan MKA, Ansari IA, Arif J. Dietary phytochemicals as potent chemotherapeutic agents against breast cancer: Inhibition of NF-κB pathway via molecular interactions in rel homology domain of its precursor protein p105. Pharmacogn Mag  2013; 9(33): 51-7.
 [http://dx.doi.org/10.4103/0973-1296.108140] [PMID:  23661994]

[66]
Vadodkar AS, Suman S, Lakshmanaswamy R, Damodaran C. Chemoprevention of breast cancer by dietary compounds. Anticancer Agents Med Chem  2012; 12(10): 1185-202.
 [http://dx.doi.org/10.2174/187152012803833008] [PMID:  22583403]

[67]
Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chem  2019; 299(July): 125124.
 [http://dx.doi.org/10.1016/j.foodchem.2019.125124] [PMID:  31288163]

[68]
George VC, Dellaire G, Rupasinghe HPV. Plant flavonoids in cancer chemoprevention: Role in genome stability. J Nutr Biochem  2017; 45: 1-14.
 [http://dx.doi.org/10.1016/j.jnutbio.2016.11.007] [PMID:  27951449]

[69]
Nabavi S, Habtemariam S, Daglia M, Nabavi S. Apigenin and breast cancers: From chemistry to medicine. Anticancer Agents Med Chem  2015; 15(6): 728-35.
 [http://dx.doi.org/10.2174/1871520615666150304120643] [PMID:  25738871]

[70]
Romano A, Martel F. The role of EGCG in breast cancer prevention and therapy. Mini Rev Med Chem  2021; 21(7): 883-98.
 [http://dx.doi.org/10.2174/1389557520999201211194445] [PMID:  33319659]

[71]
Ahmed S, Khan H, Fratantonio D, et al. Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. Phytomedicine  2019; 59: 152883.
 [http://dx.doi.org/10.1016/j.phymed.2019.152883] [PMID:  30986716]

[72]
Shukla S, Penta D, Mondal P, Meeran SM. Epigenetics of breast cancer: Clinical status of epi-drugs and phytochemicals. Adv Exp Med Biol  2019; 1152: 293-310.
 [http://dx.doi.org/10.1007/978-3-030-20301-6_16] [PMID:  31456191]

[73]
Imran M, Salehi B, Sharifi-Rad J, et al. Kaempferol: A key emphasis to its anticancer potential. Molecules  2019; 24(12): 2277.
 [http://dx.doi.org/10.3390/molecules24122277] [PMID:  31248102]

[74]
Mokbel K. Chemoprevention of breast cancer with vitamins and micronutrients: A concise review. In Vivo (Brooklyn)  2019; 33(4): 983-7.

[75]
Rose D, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther  1999; 83(3): 217-44.
 [http://dx.doi.org/10.1016/S0163-7258(99)00026-1] [PMID:  10576293]

[76]
Abel S, Riedel S, Gelderblom WCA. Dietary PUFA and cancer. Proc Nutr Soc  2014; 73(3): 361-7.
 [http://dx.doi.org/10.1017/S0029665114000585] [PMID:  24850051]

[77]
Terlikowska K, Witkowska A, Terlikowski S. Curcumin in chemoprevention of breast cancer. Postepy Hig Med Dosw  2014; 68: 571-8.
 [http://dx.doi.org/10.5604/17322693.1102294]

[78]
Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J  2009; 15(3): 223-9.
 [http://dx.doi.org/10.1111/j.1524-4741.2009.00709.x] [PMID:  19645775]

[79]
Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem  2011; 22(9): 799-806.
 [http://dx.doi.org/10.1016/j.jnutbio.2010.11.001] [PMID:  21295962]

[80]
Sinha D, Sarkar N, Biswas J, Bishayee A. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin Cancer Biol  2016; 40: 209-32.
 [http://dx.doi.org/10.1016/j.semcancer.2015.11.001]

[81]
Rabi T, Bishayee A. Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat  2009; 115(2): 223-39.
 [http://dx.doi.org/10.1007/s10549-008-0118-y] [PMID:  18636327]

[82]
Kapinova A, Kubatka P, Golubnitschaja O, et al. Dietary phytochemicals in breast cancer research: Anticancer effects and potential utility for effective chemoprevention. Environ Health Prev Med  2018; 23(1): 36.
 [http://dx.doi.org/10.1186/s12199-018-0724-1] [PMID:  30092754]

[83]
Donejko M, Niczyporuk M, Galicka E, Przylipiak A. Anti-cancer properties epigallocatechin-gallate contained in green tea. Postepy Hig Med Dosw  2013; 67: 26-34.
 [http://dx.doi.org/10.5604/17322693.1029528]

[84]
Ganai SA, Sheikh FA, Baba ZA, Mir MA, Mantoo MA, Yatoo MA. Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytother Res  2021; 35(7): 3509-32.
 [http://dx.doi.org/10.1002/ptr.7044] [PMID:  33580629]

[85]
Shafabakhsh R, Asemi Z. Quercetin: A natural compound for ovarian cancer treatment. J Ovarian Res  2019; 12(1): 55.
 [http://dx.doi.org/10.1186/s13048-019-0530-4] [PMID:  31202269]

[86]
Cossarizza A, Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S. Quercetin and cancer chemoprevention. Evidence-based Complement Altern Med 2011.

[87]
Křížová L, Dadáková K, Kašparovská J, Kašparovský T. Isoflavones. Molecules  2019; 24(6): 1076.
 [http://dx.doi.org/10.3390/molecules24061076] [PMID:  30893792]

[88]
Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in treating breast cancer: A review. SLAS Technol  2016; 21(6): 723-31.
 [http://dx.doi.org/10.1177/2211068216655524] [PMID:  27325106]

[89]
Li Y, Zhang Y, Liu X, et al. Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1. Int J Oncol  2018; 52(6): 2119-29.
 [http://dx.doi.org/10.3892/ijo.2018.4332] [PMID:  29620169]

[90]
Milani A, Basirnejad M, Shahbazi S, Bolhassani A. Carotenoids: Biochemistry, pharmacology and treatment. Br J Pharmacol  2017; 174(11): 1290-324.
 [http://dx.doi.org/10.1111/bph.13625] [PMID:  27638711]

[91]
Nicolazzi MA, Carnicelli A, Fuorlo M, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci  2018; 22(7): 2175-85.
 [PMID:  29687878]

[92]
Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: Monitoring and management. Breast Cancer Res Treat  2019; 177(2): 237-50.
 [http://dx.doi.org/10.1007/s10549-019-05303-y] [PMID:  31165940]

[93]
Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med  2020; 30(1): 22-8.
 [http://dx.doi.org/10.1016/j.tcm.2019.01.006] [PMID:  30745071]

[94]
Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila)  2011; 4(11): 1728-35.
 [http://dx.doi.org/10.1158/1940-6207.CAPR-11-0166] [PMID:  21778329]

[95]
Larsson K, Jakobsson PJ. Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment. Prostaglandins Other Lipid Mediat  2015; 120: 161-5.
 [http://dx.doi.org/10.1016/j.prostaglandins.2015.06.002] [PMID:  26100239]

[96]
Cohen V, Khuri FR. Progress in lung cancer chemoprevention. Cancer Contr  2003; 10(4): 315-24.
 [http://dx.doi.org/10.1177/107327480301000406] [PMID:  12915810]

[97]
Miriyala S, Panchatcharam M, Rengarajulu P. Cardioprotective effects of curcumin. Adv Exp Med Biol  2007; 595: 359-77.
 [http://dx.doi.org/10.1007/978-0-387-46401-5_16] [PMID:  17569220]

[98]
Ezzati M, Yousefi B, Velaei K, Safa A. A review on anti-cancer properties of Quercetin in breast cancer. Life Sci  2020; 248: 117463.
 [http://dx.doi.org/10.1016/j.lfs.2020.117463] [PMID:  32097663]

[99]
Hashemzaei M, Far AD, Yari A, et al. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol Rep  2017; 38(2): 819-28.
 [http://dx.doi.org/10.3892/or.2017.5766] [PMID:  28677813]

[100]
Hashemzaei M, Mamoulakis C, Tsarouhas K, et al. Crocin: A fighter against inflammation and pain. Food Chem Toxicol  2020; 143: 111521.
 [http://dx.doi.org/10.1016/j.fct.2020.111521] [PMID:  32640351]

[101]
Shahraki J, Rezaee R, Mohammadzehi Kenar S, et al. Umbelliprenin relieves paclitaxel-induced neuropathy. J Pharm Pharmacol  2020; 72(12): 1822-9.
 [http://dx.doi.org/10.1111/jphp.13365] [PMID:  32930406]

[102]
Rezaee R, Sheidary A, Jangjoo S, et al. Cardioprotective effects of hesperidin on carbon monoxide poisoned in rats. Drug Chem Toxicol  2021; 44(6): 668-73.
 [http://dx.doi.org/10.1080/01480545.2019.1650753] [PMID:  31412747]

[103]
Agrawal A, Fentiman IS. NSAIDs and breast cancer: A possible prevention and treatment strategy. Int J Clin Pract  2008; 62(3): 444-9.
 [http://dx.doi.org/10.1111/j.1742-1241.2007.01668.x] [PMID:  18194278]

[104]
Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: Preclinical development of novel anticancer drugs. Expert Opin Investig Drugs  2008; 17(2): 197-208.
 [http://dx.doi.org/10.1517/13543784.17.2.197] [PMID:  18230053]

[105]
Ding H, Han C, Guo D, et al. Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21 WAF1/CIP1 dependent. Int J Cancer  2008; 123(12): 2931-8.
 [http://dx.doi.org/10.1002/ijc.23895] [PMID:  18798266]

[106]
Manson MM, Farmer PB, Gescher A, Steward WP. Innovative agents in cancer prevention. Recent Results Cancer Res  2005; 166: 257-75.
 [http://dx.doi.org/10.1007/3-540-26980-0_17] [PMID:  15648195]

[107]
Gu HF, Mao XY, Du M. Prevention of breast cancer by dietary polyphenols—role of cancer stem cells. Crit Rev Food Sci Nutr  2020; 60(5): 810-25.
 [http://dx.doi.org/10.1080/10408398.2018.1551778] [PMID:  30632783]

[108]
Peiris-Pagès M, Bonuccelli G, Sotgia F, Lisanti MP. Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. Oncotarget  2018; 9(17): 13254-75.
 [http://dx.doi.org/10.18632/oncotarget.24285] [PMID:  29568355]
Cite As
Recent Advances in Inflammation & Allergy Drug Discovery

Potential of Anti-inflammatory Molecules in the Chemoprevention of Breast Cancer

Abstract

Graphical Abstract
